• Explore /
  • Poster
  • / Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial).

Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial).

Abstract Poster

Authors

null

Alexandra Leary

Institut de Cancérologie Gustave Roussy, Villejuif, France

Alexandra Leary , Stephanie Gaillard , Ignace Vergote , Jose Trigo , Carmen Maria Kahatt , Antonio Nieto , Cristian Marcelo Fernandez , Martin Cullell-Young , Ali Hassan Zeaiter , Vivek Subbiah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Other Developmental Therapeutics

Clinical Trial Registration Number

NCT02421588 and NCT02454972

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3635)

DOI

10.1200/JCO.2020.38.15_suppl.3635

Abstract #

3635

Poster Bd #

365

Abstract Disclosures

Similar Posters

First Author: Luis G. Paz-Ares

First Author: Anna F. Farago

First Author: Jose Manuel Trigo Perez

First Author: Benjamin Besse